NO20042634L - 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser - Google Patents
3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaserInfo
- Publication number
- NO20042634L NO20042634L NO20042634A NO20042634A NO20042634L NO 20042634 L NO20042634 L NO 20042634L NO 20042634 A NO20042634 A NO 20042634A NO 20042634 A NO20042634 A NO 20042634A NO 20042634 L NO20042634 L NO 20042634L
- Authority
- NO
- Norway
- Prior art keywords
- cyanoquinolines
- egf
- inhibitors
- her2 kinases
- her2
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical class C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33356801P | 2001-11-27 | 2001-11-27 | |
| PCT/US2002/037918 WO2003050090A1 (en) | 2001-11-27 | 2002-11-26 | 3-cyanoquinolines as inhibitors of egf-r and her2 kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20042634L true NO20042634L (no) | 2004-06-23 |
Family
ID=23303345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20042634A NO20042634L (no) | 2001-11-27 | 2004-06-23 | 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6821988B2 (pl) |
| EP (1) | EP1448531B1 (pl) |
| JP (1) | JP2005514384A (pl) |
| KR (1) | KR20050044599A (pl) |
| CN (1) | CN1659145A (pl) |
| AR (1) | AR037438A1 (pl) |
| AT (1) | ATE370123T1 (pl) |
| AU (1) | AU2002359489B2 (pl) |
| BR (1) | BR0214485A (pl) |
| CA (1) | CA2467573A1 (pl) |
| CO (1) | CO5580828A2 (pl) |
| DE (1) | DE60221886D1 (pl) |
| EC (1) | ECSP045122A (pl) |
| HU (1) | HUP0402228A2 (pl) |
| IL (1) | IL161921A0 (pl) |
| MX (1) | MXPA04004969A (pl) |
| NO (1) | NO20042634L (pl) |
| NZ (1) | NZ533118A (pl) |
| PL (1) | PL370137A1 (pl) |
| RU (1) | RU2309150C2 (pl) |
| TW (1) | TW200300348A (pl) |
| UA (1) | UA77469C2 (pl) |
| WO (1) | WO2003050090A1 (pl) |
| ZA (1) | ZA200405025B (pl) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| EP1648516A2 (en) * | 2003-08-01 | 2006-04-26 | Wyeth Holdings Corporation | Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| MXPA06002846A (es) * | 2003-09-15 | 2006-06-14 | Wyeth Corp | Quinolinas sustituidas como inhibidores de la enzima de la proteina tirosina cinasa. |
| US7365203B2 (en) * | 2003-09-15 | 2008-04-29 | Wyeth | Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| US7781591B2 (en) | 2006-06-13 | 2010-08-24 | Wyeth Llc | Substituted 3-cyanopyridines as protein kinase inhibitors |
| CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| EP2543376A1 (en) | 2004-04-08 | 2013-01-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| ES2401138T3 (es) | 2004-08-13 | 2013-04-17 | Genentech, Inc. | Inhibidores basados en tiazol de enzimas que usan ATP |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| TW200616612A (en) * | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
| ZA200706804B (en) | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US7624279B2 (en) * | 2005-06-29 | 2009-11-24 | Lenovo Singapore Pte. Ltd. | System and method for secure O.S. boot from password-protected HDD |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101354828B1 (ko) | 2005-11-04 | 2014-02-18 | 와이어쓰 엘엘씨 | ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합 |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| CN101466678B (zh) * | 2006-06-13 | 2012-12-26 | 惠氏公司 | 作为蛋白激酶抑制剂的经取代3-氰基吡啶 |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| CA2725598C (en) | 2008-06-17 | 2013-10-08 | Wyeth Llc | Antineoplastic combinations containing hki-272 and vinorelbine |
| MX2011001318A (es) | 2008-08-04 | 2011-03-04 | Wyeth Llc | Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina. |
| ITMI20082336A1 (it) * | 2008-12-29 | 2010-06-30 | Univ Parma | Composti inibitori irreversibili di egfr con attivita' antiproliferativa |
| RS52754B2 (sr) | 2009-01-16 | 2022-08-31 | Exelixis Inc | Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma |
| EP2416774B1 (en) | 2009-04-06 | 2015-11-04 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| EP2498751B1 (en) | 2009-11-09 | 2019-04-03 | Wyeth LLC | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| EP2581372B1 (en) * | 2010-06-09 | 2017-06-07 | Tianjin Hemay Oncology Pharmaceutical Co., Ltd. | Cyanoquinoline derivatives |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| WO2012027537A1 (en) * | 2010-08-26 | 2012-03-01 | Symphony Evolution, Inc. | Use of a receptor-type kinase modulator for treating polycystic kidney disease |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN102675287A (zh) * | 2011-03-11 | 2012-09-19 | 江苏恒瑞医药股份有限公司 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
| WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| RU2015115397A (ru) | 2012-12-21 | 2017-01-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аморфная форма производного хинолина и способ его получения |
| CN103214489B (zh) * | 2013-02-25 | 2016-10-26 | 中国人民解放军第二军医大学 | 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法 |
| ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
| CN103304494B (zh) * | 2013-06-20 | 2015-05-27 | 河北大学 | 茚(1,2-b)喹喔啉-11-酮肟衍生物及其制备方法和用途 |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| WO2016210345A1 (en) | 2015-06-25 | 2016-12-29 | The California Institute For Biomedical Research | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| WO2017117474A1 (en) * | 2015-12-30 | 2017-07-06 | Dana-Farber Cancer Institute, Inc. | Bifunctional compounds for her3 degradation and methods of use |
| JP6791979B2 (ja) * | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| MX393995B (es) | 2017-07-28 | 2025-03-24 | Yuhan Corp | Proceso mejorado para preparar derivados de aminopirimidina |
| CN110452232A (zh) * | 2019-09-17 | 2019-11-15 | 北京振东光明药物研究院有限公司 | 阿法替尼杂质化合物及其制备方法与应用 |
| CN111995618B (zh) * | 2020-09-02 | 2021-06-11 | 重庆医科大学 | 一种来那替尼杂质g的制备方法 |
| CN111943933B (zh) * | 2020-09-02 | 2021-05-28 | 重庆医科大学 | 一种来那替尼杂质d的制备方法 |
| WO2024187321A1 (zh) * | 2023-03-10 | 2024-09-19 | 甫康（上海）健康科技有限责任公司 | 含有egfr抑制剂的药物组合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4471404B2 (ja) * | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
| BRPI9914164B8 (pt) | 1998-09-29 | 2021-05-25 | American Cyanamid Co | compostos de 3-ciano quinolina |
| PL201475B1 (pl) * | 1998-09-29 | 2009-04-30 | Wyeth Corp | Podstawione 3-cyjanochinoliny jako inhibitory białkowych kinaz tyrozynowych |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| MXPA02006086A (es) * | 1999-12-29 | 2004-08-23 | Wyeth Corp | Inhibidores triciclicos de proteina-cinasas. |
| WO2002044166A1 (en) * | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
-
2002
- 2002-11-26 PL PL02370137A patent/PL370137A1/pl not_active Application Discontinuation
- 2002-11-26 RU RU2004119414/04A patent/RU2309150C2/ru not_active IP Right Cessation
- 2002-11-26 AU AU2002359489A patent/AU2002359489B2/en not_active Ceased
- 2002-11-26 KR KR1020047007951A patent/KR20050044599A/ko not_active Withdrawn
- 2002-11-26 IL IL16192102A patent/IL161921A0/xx unknown
- 2002-11-26 CA CA002467573A patent/CA2467573A1/en not_active Abandoned
- 2002-11-26 CN CN028275381A patent/CN1659145A/zh active Pending
- 2002-11-26 JP JP2003551115A patent/JP2005514384A/ja not_active Ceased
- 2002-11-26 AR ARP020104543A patent/AR037438A1/es not_active Application Discontinuation
- 2002-11-26 HU HU0402228A patent/HUP0402228A2/hu unknown
- 2002-11-26 US US10/305,438 patent/US6821988B2/en not_active Expired - Fee Related
- 2002-11-26 NZ NZ533118A patent/NZ533118A/en unknown
- 2002-11-26 WO PCT/US2002/037918 patent/WO2003050090A1/en not_active Ceased
- 2002-11-26 TW TW091134370A patent/TW200300348A/zh unknown
- 2002-11-26 AT AT02794031T patent/ATE370123T1/de not_active IP Right Cessation
- 2002-11-26 MX MXPA04004969A patent/MXPA04004969A/es active IP Right Grant
- 2002-11-26 DE DE60221886T patent/DE60221886D1/de not_active Expired - Lifetime
- 2002-11-26 UA UA20040605019A patent/UA77469C2/uk unknown
- 2002-11-26 EP EP02794031A patent/EP1448531B1/en not_active Expired - Lifetime
- 2002-11-26 BR BR0214485-9A patent/BR0214485A/pt not_active IP Right Cessation
-
2004
- 2004-05-25 CO CO04048181A patent/CO5580828A2/es not_active Application Discontinuation
- 2004-05-26 EC EC2004005122A patent/ECSP045122A/es unknown
- 2004-06-23 NO NO20042634A patent/NO20042634L/no not_active Application Discontinuation
- 2004-06-24 ZA ZA200405025A patent/ZA200405025B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200300348A (en) | 2003-06-01 |
| JP2005514384A (ja) | 2005-05-19 |
| CA2467573A1 (en) | 2003-06-19 |
| UA77469C2 (en) | 2006-12-15 |
| HUP0402228A2 (hu) | 2005-02-28 |
| MXPA04004969A (es) | 2004-08-11 |
| AU2002359489B2 (en) | 2008-10-30 |
| BR0214485A (pt) | 2004-09-14 |
| ECSP045122A (es) | 2004-07-23 |
| PL370137A1 (pl) | 2005-05-16 |
| US20030149056A1 (en) | 2003-08-07 |
| CN1659145A (zh) | 2005-08-24 |
| CO5580828A2 (es) | 2005-11-30 |
| EP1448531A1 (en) | 2004-08-25 |
| DE60221886D1 (de) | 2007-09-27 |
| IL161921A0 (en) | 2005-11-20 |
| KR20050044599A (ko) | 2005-05-12 |
| WO2003050090A1 (en) | 2003-06-19 |
| RU2004119414A (ru) | 2006-02-27 |
| EP1448531B1 (en) | 2007-08-15 |
| AR037438A1 (es) | 2004-11-10 |
| ZA200405025B (en) | 2006-12-27 |
| NZ533118A (en) | 2006-07-28 |
| ATE370123T1 (de) | 2007-09-15 |
| RU2309150C2 (ru) | 2007-10-27 |
| US6821988B2 (en) | 2004-11-23 |
| AU2002359489A1 (en) | 2003-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20042634L (no) | 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser | |
| NO20050636L (no) | Inhibitorer av tyrosinkinaser | |
| NO20052888D0 (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| IS6934A (is) | Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar | |
| NO20052595D0 (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
| DE60221977D1 (de) | Pro-pharmakon von cox-2-inhibitoren | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| NO20026010D0 (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
| IS6968A (is) | Nýir týrósínkínasa tálmar | |
| NO20033387D0 (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
| DK1370554T3 (da) | 3-(4-Amidopyrrol-2-ylmethyliden)-2-indolinon-derivater som proteinkinaseinhibitorer | |
| NO20045220L (no) | Heterocykliske inhibitorer for kinaser | |
| EP1534268A4 (en) | TYROSINE KINASE INHIBITORS | |
| NO20053356D0 (no) | Aminindazolderivater og anvendelse derav som kinaseinhibitorer. | |
| NO20053242D0 (no) | 4-substituerte benzimidazoler og deres anvendelse som inhibitorer av gastrisk sekresjon. | |
| AU2002357882A8 (en) | Small-molecule inhibitors of interleukin-2 | |
| NO20042719L (no) | Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer | |
| NO20042244L (no) | Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease | |
| NO20033854L (no) | N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse | |
| EP1651599A4 (en) | TYROSINE KINASE INHIBITORS | |
| NO20035328D0 (no) | Nye forbindelser og preparater som katepsinhibitorer | |
| EP1496897A4 (en) | Tyrosine kinase inhibitor | |
| EE200300491A (et) | 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena | |
| MXPA03009257A (es) | Derivados de isoxaxol como inhibidores de src y otras proteinas cinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |